Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
FRIEDLANDS 10.000-JAHRE-SCHOCK: Der Kupfer-Engpass hat begonnen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DPZU | ISIN: US05464C1018 | Ticker-Symbol: TCS
Tradegate
13.02.26 | 21:50
360,50 Euro
-0,36 % -1,30
1-Jahres-Chart
AXON ENTERPRISE INC Chart 1 Jahr
5-Tage-Chart
AXON ENTERPRISE INC 5-Tage-Chart
RealtimeGeldBriefZeit
359,90362,1015.02.
360,60362,9013.02.
ACCESS Newswire
441 Leser
Artikel bewerten:
(2)

MMJ International Holdings: The DEA Is Defying Supreme Court Axon in MMJ's Cannabis Case - Is DEA a rogue agency?

Duane Boise CEO of MMJ stated "Let's be clear: this isn't just administrative overreach. This is defiance of the Supreme Court by a law enforcement agency. The DEA, tasked with upholding the law, is now actively undermining it".

WASHINGTON, DC / ACCESS Newswire / April 15, 2025 / The Supreme Court has spoken. In its landmark Axon Enterprise, Inc. v. FTC decision, the Court affirmed that Americans have the right to challenge unconstitutional agency structures in federal court before enduring prolonged and potentially unlawful administrative proceedings. This ruling was meant to be a shield - protecting individuals and companies from bureaucratic abuse. But the Drug Enforcement Administration (DEA) has decided it doesn't care.

In its ongoing battle with MMJ BioPharma Cultivation, the DEA has done more than ignore Axon - it's practically dared the judiciary and the public to hold it accountable. Despite conceding that its own administrative law judges (ALJs) are unconstitutionally insulated from removal , the DEA continues to force MMJ through a regulatory meat grinder.

Duane Boise CEO of MMJ stated "Let's be clear: this isn't just administrative overreach. This is defiance of the Supreme Court by a law enforcement agency. The DEA, tasked with upholding the law, is now actively undermining it".

In Axon, the Court declared that when an agency's structure is alleged to be unconstitutional, federal courts can and should intervene immediately - no need to wait years while the flawed process grinds forward. Yet in MMJ's case, the DEA has done precisely the opposite: dismissing MMJ's federal constitutional challenge by arguing that no "irreparable harm" was done.

This argument is a slap in the face not only to MMJ but to the judiciary itself. Axon wasn't about requiring proof of harm - it was about protecting rights from being violated in the first place. The DEA's continued reliance on the Administrative Law Judge hearing process admits that the judges are improperly shielded from removal renders its entire process suspect.

And it gets worse.

MMJ Biopharma Cultivation's application to grow and research cannabis to manufacture cannabis-derived medicines for debilitating diseases like Huntington's and Multiple Sclerosis has been sitting idle since 2018. This is despite Congress mandating in the Medical Marijuana and Cannabidiol Research Expansion Act(MCREA) that DEA respond within 60 days. The DEA didn't just miss a deadline - it ignored federal law.

Add to that the stunning revelation that DEA's lead counsel, Aarathi Haig, is ineligible to practice law in New Jersey - a breach of 28 U.S.C. § 530B - and what emerges is a pattern of disregard for legality, ethics, and public duty. This situation has even prompted scrutiny from legal ethics experts and calls for audits and congressional hearings.

The agency's failure to follow Axon is not a bureaucratic oversight. It is a boldfaced assertion that the rules don't apply when the DEA doesn't want them to. This is not just about MMJ - it is about the legitimacy of every administrative action the DEA takes under structurally unconstitutional authority.

If the courts allow this to stand, the Supreme Court's ruling in Axon becomes meaningless. And if Congress stays silent, it signals that executive agencies can defy judicial authority without consequence.

America is watching. Patients are watching. The courts are watching.

And the DEA must be held to account.

For MMJ BioPharma Cultivation, this is a fight for justice. For the rest of us, it's a fight for the Constitution.

The question now is: Will the law enforcement agency charged with enforcing justice finally submit to it? The DEA's alleged obstruction, involving officials like Thomas Prevoznik,Matthew Strait and Aarathi Haig raises serious concerns about whether the agency is acting as a rogue entity, prioritizing its own agenda over the rule of law and the needs of patients.

MMJ is represented by attorney Megan Sheehan.

CONTACT:
Madison Hisey
mhisey@mmjih.com
203-231-8583

SOURCE: MMJ International Holdings



Related Documents:
  • Image 4-5-25 at 5.01?PM


© 2025 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.